The 3 Best Penny Stocks to Buy in February 2024

07:49am, Thursday, 15'th Feb 2024
Penny stocks will always provide us with investment opportunities in the event that we do not have a completely high buying power and do not want to buy fractional shares. In the large ecosystem of co
The heavy selling pressure might have exhausted for Veru Inc. (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts

Veru Inc. (VERU) Q1 2024 Earnings Call Transcript

01:36pm, Thursday, 08'th Feb 2024
Veru Inc. (VERU) Q1 2024 Earnings Call Transcript
MIAMI, FL, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for obesity, oncology, and viral induced ac
MIAMI, FL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and
MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral
MIAMI, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral indu
Veru Inc. (VERU) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.28 per share a year ago.
MIAMI, FL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for breast cancer and for viral acute respi
MIAMI, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for S

Veru Inc. (VERU) Q1 2023 Earnings Call Transcript

03:28pm, Thursday, 11'th May 2023
Veru Inc. (NASDAQ:VERU ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations & Corporate Communications Mitchell Steiner -
Veru Inc. (VERU) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.18 per share a year ago.
Veru (NASDAQ: VERU ) just reported its fiscal second-quarter results. Veru reported a loss per share of 43 cents.
Veru (VERU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
MIAMI, FL, April 27, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related disea
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE